Menu Search
Equities

Oncolytics Biotech Inc

ONYN:BER

Oncolytics Biotech Inc

Actions
  • Price (EUR)0.95
  • Today's Change-0.05 / -5.00%
  • Shares traded50.00
  • 1 Year change-34.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-28.02m
  • Incorporated1998
  • Employees29.00
  • Location
    Oncolytics Biotech Inc1167 Kensington Cres Nw Suite 210Calgary Alberta Canada T2n 1X7CALGARY T2R 0C5CanadaCAN
  • Phone+1 (403) 670-7377
  • Fax+1 (403) 283-0858
  • Websitehttps://www.oncolyticsbiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.